Abstract
We performed comparative lower respiratory tract transcriptional profiling of 52 critically ill patients with ARDS from COVID-19 or other etiologies, or without ARDS. We found no evidence of cytokine storm but instead observed complex host response dysregulation driven by genes with non-canonical roles in inflammation and immunity that were predicted to be modulated by dexamethasone. Compared to other viral ARDS, COVID-19 was characterized by impaired interferon-stimulated gene expression.
Competing Interest Statement
Dr. Christenson reports personal fees from AstraZeneca, personal fees from GlaxoSmithKline, personal fees from Amgen, personal fees from Glenmark, personal fees from Sunovion, personal fees from Genentech, personal fees from UpToDate, outside the submitted work. Dr. Sirota reports personal fees from TwoXAR. Dr. Matthay reports grants from Roche-Genentech, personal fees from Citius Pharmaceuticals, personal fees from Novartis Pharmaceutricals, outside the submitted work. Dr. Woodruff reports grants from Genentech, personal fees from Sanofi, personal fees from Regeneron, personal fees from Glenmark Pharmaceuticals, personal fees from Theravance, personal fees from NGM Pharma, outside the submitted work. Dr. Calfee reports grants and personal fees from Roche/Genentech, grants and personal fees from Bayer, personal fees from Quark Pharmaceuticals, personal fees from Prometic, personal fees from Gen1e Life Sciences, personal fees from Vasomune, grants from Quantum Leap Healthcare Collaborative, outside the submitted work. The remaining authors declare no competing interests.
Funding Statement
NIH R35 HL140026 (CSC), NIH/NIAID U19 AI1077439 (DE), NHLBI K23HL138461-01A1 (CL), K24HL137013 (PGW), F32 HL151117 (AS), Chan Zuckerberg Biohub (AOP, AB, PHS, AK, JLD), Philanthropic contributions from: Mark and Carrie Casey, Julia and Kevin Hartz, Carl Kawaja and Wendy Holcombe, Eric Keisman and Linda Nevin, Martin and Leesa Romo, Three Sisters Foundation, Diana Wagner, Jerry Yang and Akiko Yamazaki.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UCSF Institutional Review Board: protocols 17-24056 and 20-30497
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Human gene counts for the samples generated in this study can be obtained under NCBI GEO accession GSE163426. The published human lung single-cell datasets used for cell type proportions analysis can be obtained through Synapse under accessions syn21560510 and syn21560511. Code for the differential expression and cell type proportions analysis is available on GitHub (see link).
